Małgorzata Kęsik-Brodacka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Małgorzata Kęsik-Brodacka has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Andrzej Płucienniczak
Institute of Biotechnology and Antibiotics, Starościńska 5, Warszawa 02-516, Poland
3 shared publications- Diana Mikiewicz
Research Network ŁUKASIEWICZ - Institute of Biotechnology and Antibiotics, Staroscinska 5, 02-516, Warsaw, Poland
3 shared publications - Robert Olszewski
Faculty of Geodesy and Cartography, Warsaw University of Technology, Pl. Politechniki 1, 00-661 Warsaw, Poland
3 shared publications - Agnieszka Romanik
Research Network ŁUKASIEWICZ - Institute of Biotechnology and Antibiotics, Staroscinska 5, 02-516, Warsaw, Poland
2 shared publications - Boguslaw Szewczyk
Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk, ul. Abrahama 58, 80-307 Gdansk, Poland
2 shared publications Grazyna Plucienniczak
2 shared publications
Latest Publications
- Open Access
Challenges and Prospects in the Development of a Universal SARS-CoV-2 Vaccine
The development of a universal SARS-CoV-2 vaccine holds great promise for achieving broad and durable protection against existing and future coronavirus variants. The identification, selection, and rational redesign of conserved viral epitopes constitute the direct immunological foundation of universal SARS-CoV-2 vaccine development. The breadth and durability of protection are therefore primarily determined at the level of antigen and epitope design, whereas adjuvants, delivery platforms, and routes of administration serve as enabling and amplifying components rather than primary drivers of universality. Accordingly, this review discusses key determinants of universal vaccine design, including antigen selection, adjuvant utilization, and route of administration. The spike protein, particularly its receptor-binding domain, is a major antigenic target, but its high mutation rate challenges long-term vaccine efficacy. Strategies focusing on conserved epitopes in antigen designs show potential to elicit cross-neutralizing immune responses. Nanoparticle-based vaccines capable of presenting multiple homologous or heterologous antigens have demonstrated enhanced immunogenicity, broad protection in preclinical models and safety in clinical trials. The addition of next-generation adjuvants further amplifies humoral and cellular immunity beyond the capabilities of traditional aluminum-based adjuvants. Moreover, mucosal vaccine delivery may provide superior local protection at viral entry sites and limit transmission. Importantly, integrating these technological advances with epitope-centered antigen design and immunological data from vaccinated individuals will accelerate the identification of conserved epitopes and inform future vaccine design. A multidisciplinary approach combining optimized antigen engineering, novel adjuvant systems, and innovative delivery strategies is essential for the realization of a broadly protective universal SARS-CoV-2 vaccine.
Open AccessChallenges and Prospects in the Development of a Universal SARS-CoV-2 Vaccine
The development of a universal SARS-CoV-2 vaccine holds great promise for achieving broad and durable protection against existing and future coronavirus variants. The identification, selection, and rational redesign of conserved viral epitopes constitute the direct immunological foundation of universal SARS-CoV-2 vaccine development. The breadth and durability of protection are therefore primarily determined at the level of antigen and epitope design, whereas adjuvants, delivery platforms, and routes of administration serve as enabling and amplifying components rather than primary drivers of universality. Accordingly, this review discusses key determinants of universal vaccine design, including antigen selection, adjuvant utilization, and route of administration. The spike protein, particularly its receptor-binding domain, is a major antigenic target, but its high mutation rate challenges long-term vaccine efficacy. Strategies focusing on conserved epitopes in antigen designs show potential to elicit cross-neutralizing immune responses. Nanoparticle-based vaccines capable of presenting multiple homologous or heterologous antigens have demonstrated enhanced immunogenicity, broad protection in preclinical models and safety in clinical trials. The addition of next-generation adjuvants further amplifies humoral and cellular immunity beyond the capabilities of traditional aluminum-based adjuvants. Moreover, mucosal vaccine delivery may provide superior local protection at viral entry sites and limit transmission. Importantly, integrating these technological advances with epitope-centered antigen design and immunological data from vaccinated individuals will accelerate the identification of conserved epitopes and inform future vaccine design. A multidisciplinary approach combining optimized antigen engineering, novel adjuvant systems, and innovative delivery strategies is essential for the realization of a broadly protective universal SARS-CoV-2 vaccine.
- 29 December 2025
- Published by Centre of Sociological Research, NGO in Journal of International Studies
- Vol. 18 (4) , 153
Analysis of trends in financial and institutional capacity within European public health systems
The financial and institutional capacity of public health systems is an essential determinant of national socio-economic stability and resilience, especially amid fluctuating global conditions. Monitoring the efficiency and structural strength of public health management requires a thorough analysis of the dynamics, structure, and ratio of various kinds of healthcare inputs and outcomes. The aim of the research is to identify and systematise empirical patterns of change in public health indicator`s. The research is based on a comprehensive dataset spanning 2000–2023 across 34 European countries. The analysis employs 18 indicators that characterise the healthcare system across three crucial dimensions: finance, workforce and infrastructure, and health outcomes. The methodology is structured in several stages: 1) evaluating healthcare indicator fluctuations across historical periods of macroeconomic instability; 2) identifying latent system response patterns through cluster analysis; 3) generalising statistical and cluster analysis results to pointing out crucial changes in public health management as a response to global socio-economic turbulence. The findings offer an evidence base for policymakers, government executives, and academicians, supporting the development of effective regulatory frameworks aimed at strengthening the long-term financial and institutional resilience of European public health systems against future global challenges.
- 29 December 2025
- Published by Centre of Sociological Research, NGO in Journal of International Studies
- Vol. 18 (4) , 153
Analysis of trends in financial and institutional capacity within European public health systems
The financial and institutional capacity of public health systems is an essential determinant of national socio-economic stability and resilience, especially amid fluctuating global conditions. Monitoring the efficiency and structural strength of public health management requires a thorough analysis of the dynamics, structure, and ratio of various kinds of healthcare inputs and outcomes. The aim of the research is to identify and systematise empirical patterns of change in public health indicator`s. The research is based on a comprehensive dataset spanning 2000–2023 across 34 European countries. The analysis employs 18 indicators that characterise the healthcare system across three crucial dimensions: finance, workforce and infrastructure, and health outcomes. The methodology is structured in several stages: 1) evaluating healthcare indicator fluctuations across historical periods of macroeconomic instability; 2) identifying latent system response patterns through cluster analysis; 3) generalising statistical and cluster analysis results to pointing out crucial changes in public health management as a response to global socio-economic turbulence. The findings offer an evidence base for policymakers, government executives, and academicians, supporting the development of effective regulatory frameworks aimed at strengthening the long-term financial and institutional resilience of European public health systems against future global challenges.
- Open Access
- 17 June 2022
- Published by Elsevier in Computers & Operations Research
- Vol. 146, 105919
Long-term spatial and population-structured planning of non-pharmaceutical interventions to epidemic outbreaks
- 17 June 2022
- Published by Elsevier in Computers & Operations Research
- Vol. 146, 105919
Open AccessLong-term spatial and population-structured planning of non-pharmaceutical interventions to epidemic outbreaks
- Open Access
- 14 March 2022
- Published by MDPI AG in ISPRS International Journal of Geo-Information
- Vol. 11 (3) , 195
Modeling the Spatial and Temporal Spread of COVID-19 in Poland Based on a Spatial Interaction Model
This article describes an original methodology for integrating global SIR-like epidemic models with spatial interaction models, which enables the forecasting of COVID-19 dynamics in Poland through time and space. Mobility level, estimated by the regional population density and distances among inhabitants, was the determining variable in the spatial interaction model. The spatiotemporal diffusion model, which allows the temporal prediction of case counts and the possibility of determining their spatial distribution, made it possible to forecast the dynamics of the COVID-19 pandemic at a regional level in Poland. This model was used to predict incidence in 380 counties in Poland, which represents a much more detailed modeling than NUTS 3 according to the widely used geocoding standard Nomenclature of Territorial Units for Statistics. The research covered the entire territory of Poland in seven weeks of early 2021, just before the start of vaccination in Poland. The results were verified using official epidemiological data collected by sanitary and epidemiological stations. As the conducted analyses show, the application of the approach proposed in the article, integrating epidemiological models with spatial interaction models, especially unconstrained gravity models and destination (attraction) constrained models, leads to obtaining almost 90% of the coefficient of determination, which reflects the quality of the model’s fit with the spatiotemporal distribution of the validation data.
- 14 March 2022
- Published by MDPI AG in ISPRS International Journal of Geo-Information
- Vol. 11 (3) , 195
Open AccessModeling the Spatial and Temporal Spread of COVID-19 in Poland Based on a Spatial Interaction Model
This article describes an original methodology for integrating global SIR-like epidemic models with spatial interaction models, which enables the forecasting of COVID-19 dynamics in Poland through time and space. Mobility level, estimated by the regional population density and distances among inhabitants, was the determining variable in the spatial interaction model. The spatiotemporal diffusion model, which allows the temporal prediction of case counts and the possibility of determining their spatial distribution, made it possible to forecast the dynamics of the COVID-19 pandemic at a regional level in Poland. This model was used to predict incidence in 380 counties in Poland, which represents a much more detailed modeling than NUTS 3 according to the widely used geocoding standard Nomenclature of Territorial Units for Statistics. The research covered the entire territory of Poland in seven weeks of early 2021, just before the start of vaccination in Poland. The results were verified using official epidemiological data collected by sanitary and epidemiological stations. As the conducted analyses show, the application of the approach proposed in the article, integrating epidemiological models with spatial interaction models, especially unconstrained gravity models and destination (attraction) constrained models, leads to obtaining almost 90% of the coefficient of determination, which reflects the quality of the model’s fit with the spatiotemporal distribution of the validation data.
- Open Access
Attacking the Intruder at the Gate: Prospects of Mucosal Anti SARS-CoV-2 Vaccines
The sudden outbreak of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic in December 2019 caused crises and health emergencies worldwide. The rapid spread of the virus created an urgent need for the development of an effective vaccine and mass immunization to achieve herd immunity. Efforts of scientific teams at universities and pharmaceutical companies around the world allowed for the development of various types of preparations and made it possible to start the vaccination process. However, it appears that the developed vaccines are not effective enough and do not guarantee long-lasting immunity, especially for new variants of SARS-CoV-2. Considering this problem, it is promising to focus on developing a Coronavirus Disease 2019 (COVID-19) mucosal vaccine. Such a preparation applied directly to the mucous membranes of the upper respiratory tract might provide an immune barrier at the primary point of virus entry into the human body while inducing systemic immunity. A number of such preparations against SARS-CoV-2 are already in various phases of preclinical and clinical trials, and several of them are very close to being accepted for general use, constituting a milestone toward pandemic containment.
Open AccessAttacking the Intruder at the Gate: Prospects of Mucosal Anti SARS-CoV-2 Vaccines
The sudden outbreak of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic in December 2019 caused crises and health emergencies worldwide. The rapid spread of the virus created an urgent need for the development of an effective vaccine and mass immunization to achieve herd immunity. Efforts of scientific teams at universities and pharmaceutical companies around the world allowed for the development of various types of preparations and made it possible to start the vaccination process. However, it appears that the developed vaccines are not effective enough and do not guarantee long-lasting immunity, especially for new variants of SARS-CoV-2. Considering this problem, it is promising to focus on developing a Coronavirus Disease 2019 (COVID-19) mucosal vaccine. Such a preparation applied directly to the mucous membranes of the upper respiratory tract might provide an immune barrier at the primary point of virus entry into the human body while inducing systemic immunity. A number of such preparations against SARS-CoV-2 are already in various phases of preclinical and clinical trials, and several of them are very close to being accepted for general use, constituting a milestone toward pandemic containment.
- Open Access
- 5 December 2021
- Published by MDPI AG in Remote Sensing
- Vol. 13 (23) , 4946
The Effects of Climate and Bioclimate on COVID-19 Cases in Poland
The correlations between air temperatures, relative and absolute humidity, wind, cloudiness, precipitation and number of influenza cases have been extensively studied in the past. Because, initially, COVID-19 cases were similar to influenza cases, researchers were prompted to look for similar relationships. The aim of the study is to identify the effects of changes in air temperature on the number of COVID-19 infections in Poland. The hypothesis under consideration concerns an increase in the number of COVID-19 cases as temperature decreases. The spatial heterogeneity of the relationship under study during the first year and a half of the COVID-19 pandemic in Polish counties is thus revealed.
- 5 December 2021
- Published by MDPI AG in Remote Sensing
- Vol. 13 (23) , 4946
Open AccessThe Effects of Climate and Bioclimate on COVID-19 Cases in Poland
The correlations between air temperatures, relative and absolute humidity, wind, cloudiness, precipitation and number of influenza cases have been extensively studied in the past. Because, initially, COVID-19 cases were similar to influenza cases, researchers were prompted to look for similar relationships. The aim of the study is to identify the effects of changes in air temperature on the number of COVID-19 infections in Poland. The hypothesis under consideration concerns an increase in the number of COVID-19 cases as temperature decreases. The spatial heterogeneity of the relationship under study during the first year and a half of the COVID-19 pandemic in Polish counties is thus revealed.
- Open Access
Structural Effects of Disease-Related Mutations in Actin-Binding Period 3 of Tropomyosin
Tropomyosin (Tpm) is an actin-binding coiled-coil protein. In muscle, it regulates contractions in a troponin/Ca2+-dependent manner and controls the thin filament lengths at the pointed end. Due to its size and periodic structure, it is difficult to observe small local structural changes in the coiled coil caused by disease-related mutations. In this study, we designed 97-residue peptides, Tpm1.164–154 and Tpm3.1265–155, focusing on the actin-binding period 3 of two muscle isoforms. Using these peptides, we evaluated the effects of cardiomyopathy mutations: I92T and V95A in Tpm1.1, and congenital myopathy mutations R91P and R91C in Tpm3.12. We introduced a cysteine at the N-terminus of each fragment to promote the formation of the coiled-coil structure by disulfide bonds. Dimerization of the designed peptides was confirmed by gel electrophoresis in the presence and absence of dithiothreitol. Using circular dichroism, we showed that all mutations decreased coiled coil stability, with Tpm3.1265–155R91P and Tpm1.164–154I92T having the most drastic effects. Our experiments also indicated that adding the N-terminal cysteine increased coiled coil stability demonstrating that our design can serve as an effective tool in studying the coiled-coil fragments of various proteins.
Open AccessStructural Effects of Disease-Related Mutations in Actin-Binding Period 3 of Tropomyosin
Tropomyosin (Tpm) is an actin-binding coiled-coil protein. In muscle, it regulates contractions in a troponin/Ca2+-dependent manner and controls the thin filament lengths at the pointed end. Due to its size and periodic structure, it is difficult to observe small local structural changes in the coiled coil caused by disease-related mutations. In this study, we designed 97-residue peptides, Tpm1.164–154 and Tpm3.1265–155, focusing on the actin-binding period 3 of two muscle isoforms. Using these peptides, we evaluated the effects of cardiomyopathy mutations: I92T and V95A in Tpm1.1, and congenital myopathy mutations R91P and R91C in Tpm3.12. We introduced a cysteine at the N-terminus of each fragment to promote the formation of the coiled-coil structure by disulfide bonds. Dimerization of the designed peptides was confirmed by gel electrophoresis in the presence and absence of dithiothreitol. Using circular dichroism, we showed that all mutations decreased coiled coil stability, with Tpm3.1265–155R91P and Tpm1.164–154I92T having the most drastic effects. Our experiments also indicated that adding the N-terminal cysteine increased coiled coil stability demonstrating that our design can serve as an effective tool in studying the coiled-coil fragments of various proteins.
- Open Access
- 29 July 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (8) , 742
Reynoutria Rhizomes as a Natural Source of SARS-CoV-2 Mpro Inhibitors–Molecular Docking and In Vitro Study
More than a year has passed since the world began to fight the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the Coronavirus disease 2019 (COVID-19) pandemic, and still it spreads around the world, mutating at the same time. One of the sources of compounds with potential antiviral activity is Traditional Chinese Medicinal (TCM) plants used in China in the supportive treatment of COVID-19. Reynoutria japonica is important part of the Shu Feng Jie Du Granule/Capsule-TCM herbal formula, recommended by China Food and Drug Administration (CFDA) for treatment of patients with H1N1- and H5N9-induced acute lung injury and is also used in China to treat COVID-19, mainly combined with other remedies. In our study, 25 compounds from rhizomes of R. japonica and Reynoutria sachalinensis (related species), were docked into the binding site of SARS-CoV-2 main protease. Next, 11 of them (vanicoside A, vanicoside B, resveratrol, piceid, emodin, epicatechin, epicatechin gallate, epigallocatechin gallate, procyanidin B2, procyanidin C1, procyanidin B2 3,3’-di-O-gallate) as well as extracts and fractions from rhizomes of R. japonica and R. sachalinensis were tested in vitro using a fluorescent peptide substrate. Among the tested phytochemicals the best results were achieved for vanicoside A and vanicoside B with moderate inhibition of SARS-CoV-2 Mpro, IC50 = 23.10 µM and 43.59 µM, respectively. The butanol fractions of plants showed the strongest inhibition of SARS-CoV-2 Mpro (IC50 = 4.031 µg/mL for R. sachalinensis and IC50 = 7.877 µg/mL for R. japonica). As the main constituents of butanol fractions, besides the phenylpropanoid disaccharide esters (e.g., vanicosides), are highly polymerized procyanidins, we suppose that they could be responsible for their strong inhibitory properties. As inhibition of SARS-CoV-2 main protease could prevent the replication of the virus our research provides data that may explain the beneficial effects of R. japonica on COVID-19 and identify the most active compounds worthy of more extensive research.
- 29 July 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (8) , 742
Open AccessReynoutria Rhizomes as a Natural Source of SARS-CoV-2 Mpro Inhibitors–Molecular Docking and In Vitro Study
More than a year has passed since the world began to fight the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the Coronavirus disease 2019 (COVID-19) pandemic, and still it spreads around the world, mutating at the same time. One of the sources of compounds with potential antiviral activity is Traditional Chinese Medicinal (TCM) plants used in China in the supportive treatment of COVID-19. Reynoutria japonica is important part of the Shu Feng Jie Du Granule/Capsule-TCM herbal formula, recommended by China Food and Drug Administration (CFDA) for treatment of patients with H1N1- and H5N9-induced acute lung injury and is also used in China to treat COVID-19, mainly combined with other remedies. In our study, 25 compounds from rhizomes of R. japonica and Reynoutria sachalinensis (related species), were docked into the binding site of SARS-CoV-2 main protease. Next, 11 of them (vanicoside A, vanicoside B, resveratrol, piceid, emodin, epicatechin, epicatechin gallate, epigallocatechin gallate, procyanidin B2, procyanidin C1, procyanidin B2 3,3’-di-O-gallate) as well as extracts and fractions from rhizomes of R. japonica and R. sachalinensis were tested in vitro using a fluorescent peptide substrate. Among the tested phytochemicals the best results were achieved for vanicoside A and vanicoside B with moderate inhibition of SARS-CoV-2 Mpro, IC50 = 23.10 µM and 43.59 µM, respectively. The butanol fractions of plants showed the strongest inhibition of SARS-CoV-2 Mpro (IC50 = 4.031 µg/mL for R. sachalinensis and IC50 = 7.877 µg/mL for R. japonica). As the main constituents of butanol fractions, besides the phenylpropanoid disaccharide esters (e.g., vanicosides), are highly polymerized procyanidins, we suppose that they could be responsible for their strong inhibitory properties. As inhibition of SARS-CoV-2 main protease could prevent the replication of the virus our research provides data that may explain the beneficial effects of R. japonica on COVID-19 and identify the most active compounds worthy of more extensive research.
- Open Access
Ebselen derivatives are very potent dual inhibitors of SARS-CoV-2 proteases - PL pro and M pro in in vitro studies
Proteases encoded by SARS-CoV-2 constitute a promising target for new therapies against COVID-19. SARS-CoV-2 main protease (M pro , 3CL pro ) and papain-like protease (PL pro ) are responsible for viral polyprotein cleavage - a process crucial for viral survival and replication. Recently it was shown that 2-phenylbenzisoselenazol-3(2H)-one (ebselen), an organoselenium anti-inflammatory small-molecule drug, is a potent, covalent inhibitor of both the proteases and its potency was evaluated in enzymatic and anti-viral assays. In this study, we screened a collection of 23 ebselen derivatives for SARS-CoV-2 PL pro and M pro inhibitors. Our studies revealed that ebselen derivatives are potent inhibitors of both the proteases. We identified three PL pro and four M pro inhibitors superior to ebselen. Our work shows that ebselen constitutes a promising platform for development of new antiviral agents targeting both SARS-CoV-2 PL pro and M pro .
Open AccessEbselen derivatives are very potent dual inhibitors of SARS-CoV-2 proteases - PL pro and M pro in in vitro studies
Proteases encoded by SARS-CoV-2 constitute a promising target for new therapies against COVID-19. SARS-CoV-2 main protease (M pro , 3CL pro ) and papain-like protease (PL pro ) are responsible for viral polyprotein cleavage - a process crucial for viral survival and replication. Recently it was shown that 2-phenylbenzisoselenazol-3(2H)-one (ebselen), an organoselenium anti-inflammatory small-molecule drug, is a potent, covalent inhibitor of both the proteases and its potency was evaluated in enzymatic and anti-viral assays. In this study, we screened a collection of 23 ebselen derivatives for SARS-CoV-2 PL pro and M pro inhibitors. Our studies revealed that ebselen derivatives are potent inhibitors of both the proteases. We identified three PL pro and four M pro inhibitors superior to ebselen. Our work shows that ebselen constitutes a promising platform for development of new antiviral agents targeting both SARS-CoV-2 PL pro and M pro .
- Open Access
- 1 June 2020
- Published by Elsevier in Protein Expression and Purification
- Vol. 170, 105594
Bacterial expression and characterization of an anti-CD22 single-chain antibody fragment
- 1 June 2020
- Published by Elsevier in Protein Expression and Purification
- Vol. 170, 105594
Open AccessBacterial expression and characterization of an anti-CD22 single-chain antibody fragment